One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston … - Yahoo Finance

NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in treating ...

A Few Thoughts On The actual Near Future For Doxorubicin - 1UP.COM

TKI to the other, either with sorafenib followed by sunitinib SoSu or sunitinib followed by sorafenib SuSo. Everolimus was associatedwith a median PFS of . months in the in general inhabitants versus . months for placebo hazard ratio HR . self confidence ...

Research and Markets: Afinitor (Pancreatic Cancer) - Analysis and Forecasts to 2020 - CNBC

everolimus, Pancreatic cancer, Sales forecast, targeted therapy , phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, Novartis For ...

PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study - Yahoo Finance

May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting ...

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And ...  - CNBC

NATICK, Mass., May 15, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in ...

Boston Scientific (BSX) Reports Encouraging Data from PROMUS Element Study; - StreetInsider.com

Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System in ...

Xience Stents Gain European Nod For Three-Month Dual Antiplatelet Therapy - Forbes

The precise length of DAPT has been the subject of considerable discussion and research. Now the Xience Prime and Xience V everolimus-eluting stents have received the CE Mark in Europe for a DAPT length of only three months, according to an ...

Boston Scientific Reports 2-yr Results From PLATINUM Small Vessel Study - RTT News

(RTTNews) - Boston Scientific Corp. (BSX: News ) announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium, or PtCr ...

Novartis to probe Indian drug approval allegations - msnbc.com

In the case of 11, including Novartis' everolimus and aliskiren, it found that "mandatory" Phase III trials - the final stage of testing before a drug is approved - had not been conducted as required. Specifically, in the case of everolimus ...